newsfilter
← Latest News
GlobeNewswire·

Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights

– Health authority feedback on registration trials for EDP1815 in psoriasis expected by year-end –– Two Phase 2 clinical read-outs with EDP1815 in atopic dermatitis expected in 1Q and 2Q 2023 –– Phase 2 data for EDP2939 in psoriasis expected in